What it is
Soliqua and Adlyxin both contain lixisenatide, a GLP-1 drug12. GLP-1 is a hormone your gut releases when you eat3. Lixisenatide is a lab-made version of GLP-1 that acts on the same receptor1. It raises insulin when blood sugar is high, lowers glucagon (a hormone that raises blood sugar), and slows how fast the stomach empties1. Its half-life, the time it takes for half a dose to clear, is about 3 hours1. It's injected once a day, within the hour before the first meal of the day12. In a test-meal study, its effect on blood sugar after eating was strongest for that first meal and weaker for later meals1. Adlyxin was lixisenatide on its own; Soliqua combines it with an insulin, insulin glargine, in one pen12. Both are approved to improve blood sugar in adults with type 2 diabetes12.
What makes it distinct
In the US, lixisenatide now comes only inside Soliqua, mixed with insulin glargine in a fixed ratio27. The FDA lists the standalone Adlyxin as discontinued7.
What the evidence shows
Adlyxin was studied in adults with type 2 diabetes, on its own, added to diabetes pills, and added to basal (background) insulin1. Its trials compared it with placebo, a dummy treatment, and with exenatide and insulin glulisine, and against placebo it lowered HbA1c, a blood test of average blood sugar over the past few months1. Soliqua was tested in two trials in people with type 2 diabetes: one compared it with each of its two parts on its own, and the other with insulin glargine alone2. ELIXA, a heart-outcomes trial, enrolled 6,068 people with type 2 diabetes who had had a heart attack or a hospital stay for unstable angina (chest pain from poor blood flow to the heart) in the previous 180 days19. Counted together, heart-related death, heart attack, stroke and hospital stays for unstable angina did not differ significantly from placebo9. The trial ruled out a rise in that risk beyond a limit set in advance, but didn't show that lixisenatide lowered it19. In a phase 2 trial of 156 people with early Parkinson's disease, movement problems worsened less over 12 months on lixisenatide than on placebo, and lixisenatide was linked to digestive side effects such as nausea10.
Open questions
- Whether it slows Parkinson's disease. The phase 2 trial's authors say longer and larger trials are needed to know its effects and safety there10.
Worth knowing
Soliqua's dose is set in units of insulin, and each unit carries a set amount of lixisenatide, so the two always change together2. In the EU, the standalone product, sold as Lyxumia, had its approval withdrawn in December 2025 at its maker's request, for commercial reasons8.
Sources
- ADLYXIN (lixisenatide) injection, prescribing information, Sanofi (FDA, revised March 2026)
- SOLIQUA (insulin glargine and lixisenatide) injection, prescribing information, Sanofi (DailyMed; label effective March 2026)
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)
- Drugs@FDA: BLA 208471, ADLYXIN (lixisenatide)
- Drugs@FDA: BLA 208673, SOLIQUA 100/33 (insulin glargine; lixisenatide)
- FDA Purple Book monthly data download, September 2026
- European Medicines Agency: Lyxumia (lixisenatide) EPAR, withdrawn
- Pfeffer MA et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA). N Engl J Med. 2015 (PubMed 26630143)
- Meissner WG et al. Trial of Lixisenatide in Early Parkinson's Disease (LIXIPARK). N Engl J Med. 2024 (PubMed 38598572)
More in More GLP-1 drugs